Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30

$9.79−0.33 (-3.26%)

Close on Nov 12, 2026Market cap $103.30MP/E –Yield –

Biodesix ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Biodesix's ebitda for the twelve months ending Sep 30, 2026 was -$14.10M. For fiscal 2025 it was -$22.20M. The highest annual figure on record is -$20.03M in fiscal 2020.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$22.20M	–
FY2024	Dec 31, 2024	-$28.73M	–
FY2023	Dec 31, 2023	-$38.01M	–
FY2022	Dec 31, 2022	-$46.99M	–
FY2021	Dec 31, 2021	-$37.76M	–
FY2020	Dec 31, 2020	-$20.03M	–
FY2019	Dec 31, 2019	-$23.95M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$4.71M	–
Q2 FY2026	Jun 30, 2026	-$4.00M	–
Q1 FY2026	Mar 31, 2026	-$4.81M	–
Q4 FY2025	Dec 31, 2025	-$580.00K	–
Q3 FY2025	Sep 30, 2025	-$5.65M	–
Q2 FY2025	Jun 30, 2025	-$8.28M	–
Q1 FY2025	Mar 31, 2025	-$7.70M	–
Q4 FY2024	Dec 31, 2024	-$5.20M	–
Q3 FY2024	Sep 30, 2024	-$7.10M	–
Q2 FY2024	Jun 30, 2024	-$6.83M	–
Q1 FY2024	Mar 31, 2024	-$9.60M	–
Q4 FY2023	Dec 31, 2023	-$5.89M	–
Q3 FY2023	Sep 30, 2023	-$6.39M	–
Q2 FY2023	Jun 30, 2023	-$10.14M	–
Q1 FY2023	Mar 31, 2023	-$15.59M	–
Q4 FY2022	Dec 31, 2022	-$12.99M	–
Q3 FY2022	Sep 30, 2022	-$9.72M	–
Q2 FY2022	Jun 30, 2022	-$10.73M	–
Q1 FY2022	Mar 31, 2022	-$13.55M	–
Q4 FY2021	Dec 31, 2021	-$10.82M	–
Q3 FY2021	Sep 30, 2021	-$12.29M	–
Q2 FY2021	Jun 30, 2021	-$9.81M	–
Q1 FY2021	Mar 31, 2021	-$4.84M	–
Q4 FY2020	Dec 31, 2020	-$1.92M	–
Q3 FY2020	Sep 30, 2020	-$5.46M	–
Q2 FY2020	Jun 30, 2020	-$4.91M	–
Q1 FY2020	Mar 31, 2020	-$7.74M	–
Q4 FY2019	Dec 31, 2019	-$2.83M	–